Drug Safety in the Modern Age: Is It Time for a Larger-Scale Revamp of Adverse Event Case Processing?

Key Takeaways

• AI can process ICSR data within hours, cutting manual lag
• Duplication averages three submissions per case, up to ten recipients
• Agentic AI filters noise, surfaces true safety signals
• Real‑time PV could be standard in five years with proper governance

Pulse Analysis

Regulators across Europe and the United States have signaled a clear shift toward real‑time pharmacovigilance. The EMA’s 2030 vision and the FDA’s Sentinel Initiative both demand continuous safety monitoring rather than periodic snapshots. This regulatory pressure forces sponsors to rethink legacy, batch‑oriented workflows and consider end‑to‑end automation that can ingest, code, and store adverse event reports in near‑real time. Companies that fail to adapt risk falling behind compliance timelines and missing early safety signals that could affect market access.

The data explosion in drug safety creates a paradox: more reports, but more noise. Studies from TransCelerate reveal an average of three submissions per case version, with some cases sent to ten or more health‑authority recipients, inflating workload and obscuring genuine signals. Traditional manual processes struggle to cross‑analyse heterogeneous sources quickly, leading to delayed detection. Agentic AI, with its ability to observe, reason, and recommend, can triage high‑volume reports, isolate statistically significant patterns, and present only the most relevant cases to human reviewers, thereby sharpening signal intelligence without replacing expert judgment.

Implementing AI‑augmented PV requires both technology and organizational readiness. Automated pipelines for ICSR extraction, coding assistants, continuous quality layers, and AI‑driven signal evaluation are already maturing, but firms must establish robust governance to monitor model drift and ensure auditability. For products approved after limited patient exposure, rapid signal detection is especially critical. Companies that invest now could operate with near‑instantaneous case processing within five years, delivering faster patient protection, lower operational costs, and a safety function focused on high‑value expert analysis. This strategic shift not only meets upcoming regulatory expectations but also creates a sustainable competitive advantage in the evolving drug‑safety landscape.